Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ulmus parvifolia pollen is a non-standardized biologic allergen extract derived from the pollen of the Chinese elm tree (*Ulmus parvifolia*). It is primarily utilized as a diagnostic tool in allergy testing to identify individuals with hypersensitivity to Chinese elm pollen. The extract is administered via percutaneous (skin prick) or subcutaneous injection, where it triggers a localized IgE-mediated allergic response in sensitized patients, resulting in a wheal-and-flare reaction. It is manufactured by Jubilant Hollisterstier and is FDA-approved for use in allergenic testing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ulmus parvifolia pollen.